Company intelligence / Profile preview

Jarvik Heart

New York City, New York, United Statesjarvikheart.com ↗

Ownership: Private
Development stage: Commercial

Overview

Jarvik Heart’s flagship product, the Jarvik 2000 Ventricular Assist Device, has earned CE Mark certification in Europe for both bridge-to-transplant and lifetime use. In Japan, it is approved by the PMDA for bridge-to-transplant. In the US, it remains investigational with ongoing clinical trials. Over 1,000 implants have been performed worldwide with demonstrated success in sustaining and improving patient conditions while awaiting transplant or as a permanent solution[7].

Therapeutic areas: Cardiovascular
Modalities: Device (specifically, ventricular assist devices and artificial hearts)
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

Jarvik 2000

Commercial

Indications: Heart failure

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Jarvik Heart.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jarvik Heart.

Explore the full profile